Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Bluegreen who wrote (10602)	7/2/1999 12:04:00 AM
From: aknahow	Respond to of 17367

It depends on who I am working for. If using my own capital as for my own account the answer is probably yes. If as a broker/dealer I have been asked to buy or sell within certain limits I probably would stick to super messages to get the job done. The non super messages are fine but they might tip ones hand and result in one not getting the trade executed the way one wanted. But remember I don't know the answer. This is something you should ask Jim Cramer on thestreet.com.

To: Bluegreen who wrote (10602)	7/3/1999 1:04:00 PM
From: aknahow	Read Replies (1) \| Respond to of 17367

<<<<<<<We will present the meningococcemia trial results at the right scientific forum, and then publish them in a peer reviewed journal. Why not just come out and tell the world what happened in the trial? There's a good reason for waiting. In the FDAMA regulatory legislation that was passed this last year, it says that if you or your partner's sales people are going to disseminate technical information on a product, it has to come from a peer-reviewed medical journal. It is very important for our marketing effort that this data be published properly.>>>>>> <<<<<<<<<<<<<<<<<<<<<<<<technical information>>>>>>>>>>>>>>>>>>>>>>>>> Open letter to Mr. Castello: Shareholders do not need all the technical information before it is published properly. Shareholders understand that this peer publishing is indeed necessary for marketing efforts. But this does not mean that shareholders must be frozen out of the entire information loop. Just as you chose to release the total mortality, the mortality target and the additional information about the 62 patients that died before they could be enrolled, you should be able to release to share holders the non technical data. At a minimum this would be the mortality by treatment arm and placebo arm. <<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<< Bluegreen, I expect everyone to help in efforts to convince XOMA to release the non technical basic information when it becomes available.